Comprehensive Accounts of Pharmaceutical Research and Development

From Discovery to Late-Stage Process Development Volume 1

Ahmed F. Abdel-Magid (Redaktør) ; Jaan A. Pesti (Redaktør) ; Rajappa Vaidyanathan (Redaktør)

Until the latter part of the 19th century, the majority of known drugs were either herbs or extracts of active ingredients from botanical sources. At this point, the world witnessed two major cornerstone achievements that laid the foundation of modern drug discovery and development: the emergence of pharmacology as a contemporary science through the work of Schmiedeberg (considered by many as the father of modern pharmacology) at the University of Strasbourg, and
Woehler's landmark synthesis of urea from ammonium cyanate (the first synthesis of an 'organic' molecule from an 'inorganic' source) which heralded the birth of modern organic chemistry. Les mer
Vår pris
1983,-

(Innbundet) Fri frakt!
Leveringstid: Sendes innen 21 dager

Innbundet
Legg i
Innbundet
Legg i
Vår pris: 1983,-

(Innbundet) Fri frakt!
Leveringstid: Sendes innen 21 dager

Om boka

Until the latter part of the 19th century, the majority of known drugs were either herbs or extracts of active ingredients from botanical sources. At this point, the world witnessed two major cornerstone achievements that laid the foundation of modern drug discovery and development: the emergence of pharmacology as a contemporary science through the work of Schmiedeberg (considered by many as the father of modern pharmacology) at the University of Strasbourg, and
Woehler's landmark synthesis of urea from ammonium cyanate (the first synthesis of an 'organic' molecule from an 'inorganic' source) which heralded the birth of modern organic chemistry. Drug discovery has evolved from relying on luck, accident and serendipity to a complex endeavor that is at the
interface of several disciplines (e.g. pharmacology, biology, chemistry), and is built on the understanding of mechanisms and causes of diseases.

This book is produced to celebrate the evolution of drug discovery and development. It will prove useful to synthetic organic chemists in both pharmaceutical industry and in academia, and can serve as a teaching tool to students who want to learn and understand the processes and challenges of drug discovery and development with real examples from top pharmaceutical companies. The chapters contain citations of a large number of valuable selected references to the primary literature. The book
highlights the tireless efforts of discovery and process chemists, and their roles in the advancement of drug discovery and development.

The chapters presented in this book are written by a selected group of outstanding, very accomplished medicinal and process chemists with noted experiences and diverse backgrounds, representing some of the top pharmaceutical companies. The chapters highlight examples of emerging concepts, new developments and challenges arising in the discovery of new drug candidates and the development of new practical synthetic chemistry processes to produce these drug candidates on large scale. The discovery
of each drug or drug candidate is presented by the discovery chemist(s) and the process chemist(s) who developed the drug. These writing teams describe the drug's development to give the reader a complete story of drug discovery and development.

Fakta

Innholdsfortegnelse

Preface
1. Discovery and Chemical Development of Suvorexant - A Dual Orexin Antagonist for Sleep Disorder
2. Discovery of Novel Protein Fucosylation Inhibitors and Development of a Manufacturing Process To Prepare Inhibitor 6,6,6-Trifluorofucose
3. Development of Hsp90 Inhibitors for the Treatment of HER-2 Positive Solid Cancers
4. Discovery of the Novel Oxadiazole-Containing 5-Lipoxygenase Activating Protein (FLAP) Inhibitor BI 665915
5. Development of an Efficient Asymmetric Synthesis of the Chiral Quaternary 5-Lipoxygenase Activating Protein Inhibitor
6. The Discovery and Process Chemistry Development of GDC-0084, a Brain Penetrating Inhibitor of PI3K and mTOR
7. Discovery and Development of Doravirine: An Investigational Next Generation Non-Nucleside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV
8. The Discovery of Dacomitinib, a Potent Irreversible EGFR Inhibitor
9. Early and Late Stage Process Development for the Manufacture of Dacomitinib
10. Discovery and Development of the Natural Product Derivative SPI-1865 as a Gamma Secretase Modulator for Alzheimer's Disease: Part I
11. Discovery and Development of the Natural Product Derivative SPI-1865 as a Gamma Secretase Modulator for Alzheimer's Disease
12. Telaprevir: From Drug Discovery to the Manufacture of Drug Substance
Editors' Biographies
Indexes

Om forfatteren

Ahmed F. Abdel-Magid received his Bachelor's degree (1969) and Master's degree (1973) from Cairo University and his PhD (1980) from Temple University. After postdoctoral appointments at the University of South Carolina and SmithKline Beckman Pharmaceuticals, he worked at Drexel University as Teaching/Research Associate (1985-1986) then as Adjunct Professor (1986-2006). He joined the Process Chemistry Department at Wyeth Laboratories as Senior Chemist (1986-1987),
then moved to the Process Chemistry Group at Johnson & Johnson PRD (1987-2008) as a Senior Scientist and rose through the ranks to Senior Research Fellow. He joined Therachem Research Medilab in 2009 where he holds the title of Executive VP and Chief Scientific Officer.

Jaan A. Pesti received his BS degree from Long Island University, Brooklyn, NY in 1976 and his Ph.D. in organic chemistry from Columbia University in 1981. Following postdoctoral research in synthetic organic chemistry at University of California, Berkeley from 1981-1983, he joined the staff of Dupont's Medical Products Division in Wilmington, DE and Deepwater, NJ. He later transitioned to Dupont Merck Pharmaceuticals, Dupont Pharmaceuticals, and joined Bristol-Myers Squibb Pharmaceuticals in
2001. He retired from BMS in 2013 after 30 years of service, but has worked for NAL Pharma, Gelest Inc., and EnginZyme AB since that date.

Rajappa Vaidyanathan obtained his Bachelor's degree from Loyola College, Madras, and his Master's from the Indian Institute of Technology, Madras. He completed his Ph.D. in 1998 from the University of California, Irvine. After a post-doctoral appointment at Eli Lilly and Company, he joined the Chemical Process R&D group of Pharmacia Corporation, Kalamazoo, MI, and subsequently Pfizer in Groton, CT. He is currently Group Director and Head of Chemical, Synthetic and Analytical Development at
Bristol-Myers Squibb in Bangalore, India.